Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Drug EffectSafety IssuesImmunogenicity
Interventions
DRUG

GP404141

subcutaneous injection

DRUG

Nplate

subcutaneous injection

Trial Locations (6)

125284

City Clinical Hospital S.P. Botkin of the Moscow City Health Department, Moscow

194156

"National Medical Research Center in name of V.A. Almazov of the Ministry of Health of the Russian Federation", Saint Petersburg

248007

Kaluga Regional Clinical Hospital, Kaluga

354057

Oncological dispensary No. 2 of the Ministry of Health of the Krasnodar Territory, Sochi

443099

"Samara State Medical University of the Ministry of Health of the Russian Federation", Samara

450008

Federal State Budgetary Educational Institution Bashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Pharm-Holding

UNKNOWN

collaborator

I.M. Sechenov First Moscow State Medical University

OTHER

lead

Geropharm

INDUSTRY